ARIUS to present at American Association for Cancer Research Annual Meeting

    - Lead programs CD44 and Trop-2 poster presentations reveal new
    findings -

    TORONTO, April 4 /CNW/ - ARIUS Research Inc. (TSX: ARI), a biotechnology
company discovering and developing the next wave of antibody therapeutics,
today announced that new information on the preclinical activity of two of its
novel monoclonal antibodies will be presented at the Annual Meeting of the
American Association for Cancer Research (AACR), which runs from April 14-18,
2007 in Los Angeles, California. The first poster presentation will outline
the activity of ARIUS' lead anti-CD44 antibody, ARH460-16-2, against liver
cancer, a significant market in Asia and a growing concern in North America.
CD44 is an important marker for cancer stem cells that often survive treatment
and keep growing to spread tumors. Studies of patients with different types of
cancer have shown that CD44 can be linked to poorer chances of survival. ARIUS
anti-CD44 antibodies have previously been found to control tumor growth and
improve survival in breast and prostate cancer models.
    The second poster will describe the activity of two antibodies targeting
Trop-2 in a variety of solid tumors including breast and colon cancers plus
pancreatic cancer, an area without effective treatment options. Trop-2 is a
new target for drugs in cancer. Recently, increasing Trop-2 has been shown to
stimulate tumor growth. Studies in colon cancer patients found it is also
associated with more aggressive disease and cancer death.
    "Presenting our most recent findings for two of our lead programs, CD44
and Trop-2, is an excellent opportunity to showcase the potential of our
products as we look for partners," said Dr. David Young, President and CEO.
"Moreover, this important preclinical work also highlights the value and
capabilities of our FunctionFIRST(TM) platform to generate novel antibodies
with promising anti-cancer properties."

    Novel antibody ARH460-16-2 recognizes an epitope of CD44 that is highly
    expressed in liver cancers. Abstract 662, Section 27, Board 15,
    Sunday, Apr 15, 8AM - 12PM
    ARH460-16-2, a functional antibody that targets CD44, has previously been
shown to have anti-tumor and survival benefits in animal models of breast and
prostate cancers. New immunohistochemistry (IHC) studies demonstrated high
levels of ARH460-16-2 binding to primary liver tumors: 43% (21/49). The
antibody also bound more frequently to metastatic than to primary
hepatocellular carcinomas, 88% (7/8) versus 30% (11/37), and there was a trend
towards higher binding in advanced AJCC stages in comparison with earlier
stages: 0% (stage I), 12% (stage II), 50% (stage III) and 75% (stage IV). In
vivo studies are currently under way, to assess the therapeutic effect of this
antibody in an in vivo model of metastatic hepatocellular carcinoma.

    Functional antibodies targeting Trop-2 demonstrate in vivo efficacy in
    human pancreatic and other solid tumor xenograft models. Abstract 904,
    Section 5, Board 3, Sunday, Apr 15, 1PM - 5PM
    Two monoclonal antibodies directed against Trop-2, AR47A6.4.2 and
AR52A301.5, have been independently generated which, in in vitro assays,
induce cytotoxicity in pancreatic, colon, lung and ovarian cancer cell lines.
Experiments conducted using the human pancreatic BxPC-3 xenograft model
demonstrated that treatment with these antibodies resulted in tumor growth
inhibition in both prophylactic and established models. The in vivo anti-tumor
efficacy of these antibodies was examined in models of other solid tumor
cancer indications, and the anti-tumor effect in human pancreatic cancer was
substantiated by a second model of human pancreatic cancer. With the aim of
bringing these antibodies to the clinic, the selection of an animal model for
toxicology studies was undertaken. Results from these studies have
demonstrated a very similar expression pattern between humans and cynomolgus
monkeys, thereby providing a relevant candidate model for pre-clinical

    The Annual meeting of the American Association for Cancer Research (AACR)
will be held at the Los Angeles Convention Center in Los Angeles, California
and runs from April 14-18, 2007. Additional information about the AACR and
detailed abstracts of ARIUS' poster presentations can be found at

    About ARIUS
    ARIUS is a biotechnology company discovering and developing the next wave
of antibody therapeutics. Established in 1999, ARIUS has built a proprietary
technology platform, FunctionFIRST(TM), that rapidly identifies and selects
antibodies based on their functional ability to affect disease. This antibody
generation engine has enabled ARIUS to assemble a portfolio of more than 400
antibody candidates. In addition to the antibodies it is developing in-house,
ARIUS has ongoing partnerships with key biotechnology and drug development
companies. ARUIS is listed on the TSX under the symbol "ARI". For further
information, visit

    Forward-Looking Statements
    Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.

         The TSX has not reviewed and does not accept responsibility
               for the adequacy or accuracy of this statement.

    %SEDAR: 00013708E

For further information:

For further information: Helen Findlay, Executive Vice-President, (416)
862-2323 ext. 223,; James Smith, Investor Relations,
(416) 815-0700 ext. 229,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890